Estradiol increases platelet aggregation in PlA1/A1 individuals - 18/08/11

Résumé |
Background |
The platelet glycoprotein IIb/IIIa receptor is a key mediator of platelet aggregation and intracoronary thrombosis. Studies have suggested that hormone replacement therapy (HRT) may increase coronary events in postmenopausal women.
Objectives |
We sought to characterize the relationship between the estrogen concentration expected in HRT and platelet aggregation.
Design and Results |
Platelet aggregation studies were performed using epinephrine on 30 healthy individuals (15 PlA1/A1 and 15 PlA1/A2) before and after incubation with β-estradiol (E2) (10−11 mol/L). The effect of E2 10−11 mol/L on PlA1/A1 platelets demonstrated a significant increase (P = .03) in aggregation compared with baseline. In contrast, with the same concentration of E2, aggregation of PlA1/A2 platelets decreased significantly compared with baseline (P < .0001).
Conclusions |
Estrogen concentration similar to that expected in HRT resulted in an increase in platelet aggregation in PlA1/A1 individuals, but not in PlA1/A2 individuals. The data may provide further insight for the increase in coronary events seen in HRT clinical trials and suggest that further evaluation is needed to better define the role of pharmacogenetics in HRT.
Le texte complet de cet article est disponible en PDF.Plan
| Support: Dr Boudoulas received support from the Samuel J. Roessler Research Scholarship, The Ohio State University College of Medicine and Public Health (Columbus, OH). Dr Cooke is supported by NIH career development grant (K23 HL004483) (Bethesda, MD). |
|
| Guest editor of this manuscript is A. Michael Lincoff, MD. |
Vol 152 - N° 1
P. 136-139 - juillet 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
